Issie Kirby
Stock Analyst at Redburn Atlantic
(0.97)
# 3,726
Out of 4,883 analysts
7
Total ratings
25%
Success rate
-0.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Issie Kirby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Upgrades: Buy | $85 → $115 | $82.94 | +38.65% | 2 | Feb 3, 2025 | |
| ALC Alcon | Upgrades: Neutral | n/a | $86.80 | - | 1 | Oct 10, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Buy | $60 | $16.25 | +269.23% | 1 | May 30, 2024 | |
| PODD Insulet | Initiates: Buy | $235 | $300.70 | -21.85% | 1 | May 30, 2024 | |
| COO The Cooper Companies | Upgrades: Buy | $125 | $73.29 | +70.56% | 2 | Mar 19, 2024 |
DexCom
Feb 3, 2025
Upgrades: Buy
Price Target: $85 → $115
Current: $82.94
Upside: +38.65%
Alcon
Oct 10, 2024
Upgrades: Neutral
Price Target: n/a
Current: $86.80
Upside: -
Tandem Diabetes Care
May 30, 2024
Initiates: Buy
Price Target: $60
Current: $16.25
Upside: +269.23%
Insulet
May 30, 2024
Initiates: Buy
Price Target: $235
Current: $300.70
Upside: -21.85%
The Cooper Companies
Mar 19, 2024
Upgrades: Buy
Price Target: $125
Current: $73.29
Upside: +70.56%